WO2002022809A3 - PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST - Google Patents
PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST Download PDFInfo
- Publication number
- WO2002022809A3 WO2002022809A3 PCT/US2001/029229 US0129229W WO0222809A3 WO 2002022809 A3 WO2002022809 A3 WO 2002022809A3 US 0129229 W US0129229 W US 0129229W WO 0222809 A3 WO0222809 A3 WO 0222809A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- murine
- tlr8
- tlr7
- tlr9
- well
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT01971181T ATE510850T1 (en) | 2000-09-15 | 2001-09-17 | METHOD FOR HIGH-THROUGHPUT SCREENING OF CPG-BASED IMMUNAGONISTS AND ANTAGONISTS |
EP01971181A EP1366077B1 (en) | 2000-09-15 | 2001-09-17 | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
AU2001291096A AU2001291096A1 (en) | 2000-09-15 | 2001-09-17 | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
JP2002527251A JP2005500806A (en) | 2000-09-15 | 2001-09-17 | Process for high-throughput screening of immune agonist / immunoantagonists based on CpG |
CA002419894A CA2419894A1 (en) | 2000-09-15 | 2001-09-17 | Process for high throughput screening of cpg-based immuno-agonist/antagonist |
DK01971181.1T DK1366077T3 (en) | 2000-09-15 | 2001-09-17 | Method for screening in large quantities of CpG-based immunoagonists / antagonists |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23303500P | 2000-09-15 | 2000-09-15 | |
US60/233,035 | 2000-09-15 | ||
US26365701P | 2001-01-23 | 2001-01-23 | |
US60/263,657 | 2001-01-23 | ||
US29172601P | 2001-05-17 | 2001-05-17 | |
US60/291,726 | 2001-05-17 | ||
US30021001P | 2001-06-22 | 2001-06-22 | |
US60/300,210 | 2001-06-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002022809A2 WO2002022809A2 (en) | 2002-03-21 |
WO2002022809A9 WO2002022809A9 (en) | 2003-03-20 |
WO2002022809A3 true WO2002022809A3 (en) | 2003-10-02 |
Family
ID=27499675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/029229 WO2002022809A2 (en) | 2000-09-15 | 2001-09-17 | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
Country Status (8)
Country | Link |
---|---|
US (2) | US6943240B2 (en) |
EP (1) | EP1366077B1 (en) |
JP (1) | JP2005500806A (en) |
AT (1) | ATE510850T1 (en) |
AU (1) | AU2001291096A1 (en) |
CA (1) | CA2419894A1 (en) |
DK (1) | DK1366077T3 (en) |
WO (1) | WO2002022809A2 (en) |
Families Citing this family (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
ZA989147B (en) * | 1997-10-17 | 2000-04-07 | Genentech Inc | Human toll homologues. |
EP1067956B1 (en) * | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
DE69927495T2 (en) * | 1998-05-14 | 2006-07-06 | Coley Pharmaceutical Group, Inc., Wellesley | METHOD OF REGULATING HEMATOPOESIS BY USING CPG OLIGONUCLEOTIDES |
DE69932717T2 (en) * | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
EP2204186B1 (en) * | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
JP2003510282A (en) * | 1999-09-25 | 2003-03-18 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Immunostimulatory nucleic acids |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
WO2001095935A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
CA2410371C (en) * | 2000-06-22 | 2015-11-17 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
JP2002034565A (en) | 2000-07-19 | 2002-02-05 | Japan Science & Technology Corp | Receptor protein specifically recognizing bacterial dna |
WO2002022809A2 (en) * | 2000-09-15 | 2002-03-21 | Coley Pharmaceutical Gmbh | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
ATE398175T1 (en) * | 2000-12-08 | 2008-07-15 | Coley Pharmaceuticals Gmbh | CPG-TYPE NUCLEIC ACIDS AND METHODS OF USE THEREOF |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
AU2002361468A1 (en) * | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
WO2003015711A2 (en) | 2001-08-17 | 2003-02-27 | Coley Pharmaceutical Group, Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
CA2461315A1 (en) * | 2001-10-05 | 2003-04-17 | Coley Pharmaceutical Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
JP2005519990A (en) * | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US7608750B2 (en) * | 2001-11-22 | 2009-10-27 | Japan Science And Technology Agency | Nonhuman model animal unresponsive to immunopotentiating synthetic compound |
AU2002360791A1 (en) * | 2001-12-18 | 2003-06-30 | Health Research, Inc. | Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
US7615227B2 (en) * | 2001-12-20 | 2009-11-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce angiogenesis |
ES2543710T3 (en) | 2002-04-04 | 2015-08-21 | Zoetis Belgium S.A. | Immunostimulatory oligonucleotides containing G and U |
WO2003103586A2 (en) * | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
CN1753687A (en) * | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
WO2004053452A2 (en) * | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
WO2004070344A2 (en) * | 2003-02-04 | 2004-08-19 | Bayer Healthcare Ag | Method of screening for agents which modulate the activity of tlr9 |
WO2004071459A2 (en) | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | Selective modulation of tlr-mediated biological activity |
US20040191833A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
US20040235770A1 (en) * | 2003-04-02 | 2004-11-25 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
WO2004094671A2 (en) * | 2003-04-22 | 2004-11-04 | Coley Pharmaceutical Gmbh | Methods and products for identification and assessment of tlr ligands |
KR20060016817A (en) * | 2003-06-20 | 2006-02-22 | 콜리 파마슈티칼 게엠베하 | Small molecule toll-like receptor (tlr) antagonists |
EP1653914A4 (en) | 2003-08-12 | 2008-10-29 | 3M Innovative Properties Co | Oxime substituted imidazo-containing compounds |
US7897597B2 (en) | 2003-08-27 | 2011-03-01 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
WO2005023190A2 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
WO2005030259A2 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
BRPI0414856A (en) | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | alkoxy-substituted imidazoquinolines |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
AU2004291101A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
EP1682544A4 (en) | 2003-11-14 | 2009-05-06 | 3M Innovative Properties Co | Hydroxylamine substituted imidazo ring compounds |
BRPI0416936A (en) | 2003-11-25 | 2007-01-16 | 3M Innovative Properties Co | substituted imidazo ring systems and methods |
US20050208470A1 (en) * | 2003-12-16 | 2005-09-22 | University Of Massachusetts | Toll-like receptor assays |
US8802853B2 (en) | 2003-12-29 | 2014-08-12 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
AU2004312508A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
JP2007526253A (en) * | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Immunostimulatory viral RNA oligonucleotide |
TW200612932A (en) | 2004-03-24 | 2006-05-01 | 3M Innovative Properties Co | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
US20050244410A1 (en) * | 2004-04-29 | 2005-11-03 | Ashlyn Bassiri | Toll-like receptor 9 effector agents and uses thereof |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
EP1781325A2 (en) | 2004-07-18 | 2007-05-09 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
GB0424497D0 (en) * | 2004-11-05 | 2004-12-08 | Univ Sheffield | Anti-inflammatory agent |
WO2006056478A1 (en) | 2004-11-29 | 2006-06-01 | Klinikum Der Universität Regensburg | Kits and methods for detecting methylated dna |
WO2006056480A2 (en) * | 2004-11-29 | 2006-06-01 | Klinikum Der Universität Regensburg | Means and methods for detecting methylated dna |
JP5313502B2 (en) | 2004-12-30 | 2013-10-09 | スリーエム イノベイティブ プロパティズ カンパニー | Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds |
WO2006074003A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
KR100980898B1 (en) * | 2005-01-28 | 2010-09-07 | 권형주 | Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell |
CA2597092A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
DE102005005642A1 (en) * | 2005-02-06 | 2006-08-10 | Phenion Gmbh & Co. Kg | Cosmetic or pharmaceutical preparations containing nucleic acids comprising sequences suitable for the formation of stem-loop secondary structures |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
US7498409B2 (en) * | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
US7700728B2 (en) * | 2005-03-24 | 2010-04-20 | Schering Corporation | Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors |
JP2008148556A (en) * | 2005-03-31 | 2008-07-03 | Univ Of Tokyo | METHOD FOR SCREENING AUXILIARY AGENT CAPABLE OF PROMOTING EXPRESSION INDUCTION OF INTERFERON-alpha AND/OR -beta (IFN-alpha/beta) |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
EP1863814A1 (en) | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
US20060241076A1 (en) * | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
AU2006266503B2 (en) | 2005-07-01 | 2011-12-08 | Index Pharmaceuticals Ab | Immunostimulatory method |
ES2435531T3 (en) | 2005-07-01 | 2013-12-20 | Index Pharmaceuticals Ab | Modulation of steroid responsiveness |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
WO2007038720A2 (en) * | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
AU2006306805A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
KR20080075107A (en) * | 2005-11-11 | 2008-08-14 | 화이자 인코포레이티드 | Combinations and methods of using an immunomodulatory oligodeoxynucleotide |
EP1957647B1 (en) | 2005-11-25 | 2015-03-04 | Zoetis Belgium S.A. | Immunostimulatory oligoribonucleotides |
US20090288176A1 (en) * | 2006-04-19 | 2009-11-19 | Genentech, Inc. | Novel Gene Disruptions, Compositions and Methods Relating Thereto |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
EP2056880A4 (en) * | 2006-08-16 | 2010-10-13 | Protiva Biotherapeutics Inc | Nucleic acid modulation of toll-like receptor-mediated immune stimulation |
MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
CN104789638A (en) * | 2007-07-23 | 2015-07-22 | 帝斯曼知识产权资产管理有限公司 | Butanol production in a eukaryotic cell |
US20100040576A1 (en) * | 2007-12-18 | 2010-02-18 | The Texas A&M University System | Modified Oligonucleotides For The Treatment Of Hepatitis C Infection |
JP2011529501A (en) * | 2008-07-28 | 2011-12-08 | イデラ ファーマシューティカルズ インコーポレイテッド | Regulation of Toll-like receptor 9 expression by antisense oligonucleotides |
CN102076813B (en) * | 2008-11-11 | 2016-05-18 | 默克专利有限公司 | Organic electroluminescence device |
US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
PL2411521T3 (en) | 2009-03-25 | 2015-08-31 | Univ Texas | Compositions for stimulation of mammalian innate immune resistance to pathogens |
FR2945538B1 (en) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF THE BETA-AMYLOID PEPTIDE. |
WO2011005761A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc | Novel nucleic acid prodrugs and methods use thereof |
US20110009477A1 (en) * | 2009-07-08 | 2011-01-13 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
JP5969458B2 (en) * | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | Albumin derivatives and variants |
EP2617426B1 (en) * | 2010-09-17 | 2016-08-10 | Japan Science and Technology Agency | Inhibitor of hmgb protein-mediated immune response activation |
WO2012039448A1 (en) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | Asymmetric auxiliary group |
US20130337453A1 (en) * | 2010-10-21 | 2013-12-19 | Tufts University | Extracellular mitochondria-based screening and treatment |
WO2012135549A2 (en) * | 2011-03-29 | 2012-10-04 | Dynavax Technologies Corporation | Tlr8 transgenic animals |
RU2014105311A (en) | 2011-07-19 | 2015-08-27 | Уэйв Лайф Сайенсес Пте. Лтд. | METHODS FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
JP2015509091A (en) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | Humanized antibody |
US9556439B2 (en) * | 2012-02-09 | 2017-01-31 | Bavarian Nordic A/S | Agonists and antagonists of toll-like receptor (TLR) 13 |
DK2825556T3 (en) | 2012-03-16 | 2018-04-16 | Albumedix As | albumin Variants |
CN104684893B (en) | 2012-07-13 | 2016-10-26 | 日本波涛生命科学公司 | Asymmetric auxiliary group |
KR20150082422A (en) | 2012-11-08 | 2015-07-15 | 노보자임스 바이오파마 디케이 에이/에스 | Albumin variants |
WO2014110368A1 (en) * | 2013-01-11 | 2014-07-17 | The California Institute For Biomedical Research | Bovine fusion antibodies |
WO2015010100A2 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
EP3095459A4 (en) * | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
US10144933B2 (en) * | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
ES2917473T3 (en) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | chiral design |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
CA2989966A1 (en) | 2015-08-20 | 2017-02-23 | Albumedix A/S | Albumin variants and conjugates |
CN111417401A (en) * | 2017-06-30 | 2020-07-14 | 皇家墨尔本理工大学 | A method of treatment |
WO2020041590A1 (en) * | 2018-08-23 | 2020-02-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tlr9 ligand trap |
US11393560B2 (en) * | 2018-11-13 | 2022-07-19 | Recursion Pharmaceuticals, Inc. | Systems and methods for high throughput compound library creation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055386A1 (en) * | 2000-01-25 | 2001-08-02 | Glaxosmithkline | Toll-like receptor |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567604A (en) | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
JP3626187B2 (en) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | Plasmid suitable for gene therapy |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
DE19502912A1 (en) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
EP0810882A4 (en) | 1995-02-09 | 1999-05-19 | Icn Pharmaceuticals | Methods and compositions for regulation of cd28 expression |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
WO1999020756A2 (en) | 1997-10-17 | 1999-04-29 | Genentech, Inc. | Human toll homologues |
PL334197A1 (en) | 1996-12-27 | 2000-02-14 | Icn Pharmaceuticals | Oligonucleotidic aptamers of high g content and methods of modulating immunilogical response |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP1798288B1 (en) | 1997-05-07 | 2009-09-16 | Schering Corporation | Human Toll-like receptor proteins, related reagents and methods |
CA2301575C (en) | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
EP1009440B1 (en) * | 1997-07-03 | 2008-09-17 | MacFarlane, Donald E. | Method for inhibiting immunostimulatory dna associated responses |
EP1067956B1 (en) | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
DE69927495T2 (en) | 1998-05-14 | 2006-07-06 | Coley Pharmaceutical Group, Inc., Wellesley | METHOD OF REGULATING HEMATOPOESIS BY USING CPG OLIGONUCLEOTIDES |
DE69932717T2 (en) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY |
EP1100807A1 (en) | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
EP1108017A2 (en) | 1998-09-03 | 2001-06-20 | Coley Pharmaceutical GmbH | G-motif oligonucleotides and uses thereof |
ATE442774T1 (en) | 1999-01-14 | 2009-10-15 | Japan Science & Tech Agency | MYOD-KNOCKOUT MOUSE AS A BACTERIAL CELL WALL COMPONENT-UNRESPENSIVE ANIMAL MODEL |
EP1177439B1 (en) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening for immunostimulatory dna functional modifiers |
AU6051800A (en) | 1999-06-16 | 2001-01-02 | University Of Iowa Research Foundation, The | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
JP2003510282A (en) | 1999-09-25 | 2003-03-18 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Immunostimulatory nucleic acids |
ATE333284T1 (en) | 1999-09-27 | 2006-08-15 | Coley Pharm Group Inc | METHOD USING IMMUNOSTIMULATIVE INTERFERON INDUCED BY NUCLEIC ACIDS |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
ATE421584T1 (en) | 1999-11-02 | 2009-02-15 | Novartis Vaccines & Diagnostic | CPG RECEPTOR (CPG-R) AND RELATED METHODS |
WO2001095935A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20040131628A1 (en) | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US6339630B1 (en) * | 2000-05-18 | 2002-01-15 | The United States Of America As Represented By The United States Department Of Energy | Sealed drive screw operator |
CA2410371C (en) * | 2000-06-22 | 2015-11-17 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20020165178A1 (en) * | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
US20020091097A1 (en) * | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
WO2002022809A2 (en) | 2000-09-15 | 2002-03-21 | Coley Pharmaceutical Gmbh | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
ATE398175T1 (en) | 2000-12-08 | 2008-07-15 | Coley Pharmaceuticals Gmbh | CPG-TYPE NUCLEIC ACIDS AND METHODS OF USE THEREOF |
US20030055014A1 (en) * | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
EP1412390A2 (en) | 2001-07-26 | 2004-04-28 | Tanox, Inc. | Agents that activate or inhibit toll-like receptor 9 |
WO2003012061A2 (en) * | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
WO2003015711A2 (en) * | 2001-08-17 | 2003-02-27 | Coley Pharmaceutical Group, Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
US20030067902A1 (en) * | 2001-09-21 | 2003-04-10 | Skeba Kirk W. | Method for providing multiple certified radio modules with a baseband |
CA2461315A1 (en) * | 2001-10-05 | 2003-04-17 | Coley Pharmaceutical Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
JP2005519990A (en) * | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Methods and products for enhancing immune responses using imidazoquinoline compounds |
ES2318615T3 (en) | 2001-11-16 | 2009-05-01 | Coley Pharmaceutical Group, Inc. | N- (4- (4-AMINO-2-ETIL-1H-IMIDAZO (4,5-C) QUINOLIN-1-IL) BUTIL) METHANOSULPHONAMIDE, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES ITSELF. |
ES2543710T3 (en) | 2002-04-04 | 2015-08-21 | Zoetis Belgium S.A. | Immunostimulatory oligonucleotides containing G and U |
WO2003103586A2 (en) * | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
WO2004007743A2 (en) | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
WO2004026888A2 (en) | 2002-09-19 | 2004-04-01 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
CN1753687A (en) * | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
US7956043B2 (en) * | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US20040235770A1 (en) | 2003-04-02 | 2004-11-25 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
WO2004094671A2 (en) | 2003-04-22 | 2004-11-04 | Coley Pharmaceutical Gmbh | Methods and products for identification and assessment of tlr ligands |
KR20060016817A (en) * | 2003-06-20 | 2006-02-22 | 콜리 파마슈티칼 게엠베하 | Small molecule toll-like receptor (tlr) antagonists |
WO2005030259A2 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
US8188254B2 (en) * | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
JP2007526253A (en) | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Immunostimulatory viral RNA oligonucleotide |
JP2007531746A (en) * | 2004-04-02 | 2007-11-08 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Immunostimulatory nucleic acid for inducing an IL-10 response |
CA2574090A1 (en) * | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
-
2001
- 2001-09-17 WO PCT/US2001/029229 patent/WO2002022809A2/en active Application Filing
- 2001-09-17 DK DK01971181.1T patent/DK1366077T3/en active
- 2001-09-17 JP JP2002527251A patent/JP2005500806A/en not_active Withdrawn
- 2001-09-17 CA CA002419894A patent/CA2419894A1/en not_active Abandoned
- 2001-09-17 AT AT01971181T patent/ATE510850T1/en not_active IP Right Cessation
- 2001-09-17 US US09/954,987 patent/US6943240B2/en not_active Expired - Fee Related
- 2001-09-17 EP EP01971181A patent/EP1366077B1/en not_active Expired - Lifetime
- 2001-09-17 AU AU2001291096A patent/AU2001291096A1/en not_active Abandoned
-
2005
- 2005-03-18 US US11/084,777 patent/US7820379B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055386A1 (en) * | 2000-01-25 | 2001-08-02 | Glaxosmithkline | Toll-like receptor |
Non-Patent Citations (12)
Title |
---|
BAUER STEFAN ET AL: "Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 16, 31 July 2001 (2001-07-31), July 31, 2001, pages 9237 - 9242, XP002221247, ISSN: 0027-8424 * |
CHUANG TSUNG-HSIEN ET AL: "Toll-like receptor 9 mediates CpG-DNA signaling.", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 71, no. 3, March 2002 (2002-03-01), March, 2002, pages 538 - 544, XP009001226, ISSN: 0741-5400 * |
DATABASE EMBL [online] EBI; 2 August 1999 (1999-08-02), XP002221249, retrieved from EMBL Database accession no. AAY05867 * |
DATABASE EMBL [online] EBI; 5 April 2001 (2001-04-05), XP002221250, retrieved from EMBL Database accession no. AF348140 * |
DU XIN ET AL: "Three novel mammalian toll-like receptors: Gene structure, expression, and evolution.", EUROPEAN CYTOKINE NETWORK, vol. 11, no. 3, September 2000 (2000-09-01), pages 362 - 371, XP009000972, ISSN: 1148-5493 * |
HEMMI HIROAKI ET AL: "A Toll-like receptor recognizes bacterial DNA.", NATURE (LONDON), vol. 408, no. 6813, 2000, pages 740 - 745, XP002221246, ISSN: 0028-0836 * |
HOSHINO K ET AL: "Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 APR 1999, vol. 162, no. 7, 1 April 1999 (1999-04-01), pages 3749 - 3752, XP002221244, ISSN: 0022-1767 * |
KOPP E B ET AL: "The Toll-receptor family and control of innate immunity", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 11, no. 1, 1 February 1999 (1999-02-01), pages 13 - 18, XP004257650, ISSN: 0952-7915 * |
MUZIO MARTA ET AL: "Toll-like receptors.", MICROBES AND INFECTION, vol. 2, no. 3, March 2000 (2000-03-01), pages 251 - 255, XP002221245, ISSN: 1286-4579 * |
NATURE, vol. 409, February 2001 (2001-02-01), pages 646, XP002224870 * |
TAKEUCHI O ET AL: "TLR6: A novel member of an expanding Toll-like receptor family.", GENE (AMSTERDAM), vol. 231, no. 1-2, 29 April 1999 (1999-04-29), pages 59 - 65, XP004166778, ISSN: 0378-1119 * |
XIN DU ET AL: "THREE NOVEL MAMMALIAN TOLL-LIKE RECEPTORS: GENE STRUCTURE, EXPRESSION, AND EVOLUTION", EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD., MONTROUGE, FR, vol. 11, no. 3, September 2000 (2000-09-01), pages 1 - 14, XP002944897, ISSN: 1148-5493 * |
Also Published As
Publication number | Publication date |
---|---|
DK1366077T3 (en) | 2011-09-12 |
US6943240B2 (en) | 2005-09-13 |
EP1366077A2 (en) | 2003-12-03 |
WO2002022809A2 (en) | 2002-03-21 |
WO2002022809A9 (en) | 2003-03-20 |
AU2001291096A1 (en) | 2002-03-26 |
US20030104523A1 (en) | 2003-06-05 |
JP2005500806A (en) | 2005-01-13 |
EP1366077B1 (en) | 2011-05-25 |
CA2419894A1 (en) | 2002-03-21 |
US7820379B2 (en) | 2010-10-26 |
ATE510850T1 (en) | 2011-06-15 |
US20050181422A1 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002022809A3 (en) | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST | |
WO2003086280A3 (en) | Immunostimulatory g,u-containing oligoribonucleotides | |
MXPA03000627A (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus. | |
YU19903A (en) | Novel receptor nucleic acids and polypeptides | |
WO2002008256A3 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
AU2002259305A8 (en) | High affinity ligand for p75 neurotrophin receptor | |
EP1408986A4 (en) | Proteomimetic compounds and methods | |
WO2003068798A3 (en) | Oligonucleotide analogues and methods of use for modulating gene expression | |
WO2002008251A3 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
WO2004103304A3 (en) | Treatment of t-cell mediated diseases | |
WO2003016475A3 (en) | Nucleic acid and amino acid sequences involved in pain | |
EP1594889A4 (en) | Nell peptide expression systems and bone formation activity of nell peptide | |
EP1141286A4 (en) | Cytokine receptor chain | |
EP1668030A4 (en) | A method of improving efficacy of biological response-modifying proteins and the exemplary muteins | |
WO2002060917A3 (en) | Method to treat hemophilia | |
PL343411A1 (en) | Novel compositions of eprosartan | |
DE69923587D1 (en) | NON-PEPTIDIC ANTAGONISTS OF GLP-1 RECEPTOR AND METHODS OF USE | |
WO2002070001A3 (en) | Use of lp82 to treat hematopoietic disorders | |
WO2003106625A3 (en) | Hammerhead ribozymes | |
AU7525398A (en) | Inhibitors for urokinase receptor | |
PT1446733E (en) | Glycosylphosphatidylinositol containing polypeptides | |
MXPA05009428A (en) | Compositions and methods for preventing and treating endotoxin-related diseases and conditions. | |
MXPA04005176A (en) | N-ureido-piperidines as antagonists viii for ccr-3 receptor. | |
WO2000075305A3 (en) | Candida albicans genes and proteins coded by said genes | |
WO2001023540A3 (en) | P-glycoproteins and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2419894 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 524361 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001291096 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002527251 Country of ref document: JP |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/20-20/20; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001971181 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001971181 Country of ref document: EP |